PMEF
NRIX icon

Point72 Middle East FZE’s Nurix Therapeutics NRIX Stock Holding History

Point72 Middle East FZE’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-651
Closed -$5.12K – 1758
2023
Q3 		$5.12K Buy
+651
New +$5.94K ﹤0.01% 1375

Other funds holding NRIX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Point72 Middle East FZE's NRIX Position: Q4 2023 in Review

Point72 Middle East FZE sold out of Nurix Therapeutics (NRIX) in Q4 2023, closing a stake of 651 shares — an estimated $5.12K sold.

Point72 Middle East FZE first reported a position in NRIX in Q3 2023 and held it in 1 quarter. The position peaked at $5.12K in Q3 2023. 130 funds tracked by Wall St. Rank hold NRIX as of Q4 2023.

  • Point72 Middle East FZE reported no remaining Nurix Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 651 Nurix Therapeutics shares in Q4 2023, an estimated $5.12K.
  • Point72 Middle East FZE first reported a position in Nurix Therapeutics in Q3 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's Nurix Therapeutics position peaked at $5.12K in Q3 2023.
  • 130 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2023.

Based on Point72 Middle East FZE's 13F filing for Q4 2023, filed 14 Feb 2024.